<?xml version="1.0"?>
<hexML>
  <head>
    <title>Novartis Pharma  US </title>
    <count>377</count>
    <description>Contains 377 releases</description>
    <flastmod date="2026-03-29T12:26:09"/>
  </head>
  <body>
    <press_releases>
      <press_release language="en" type="5" id="137507" joint_id="137507">
        <published date="2026-03-29T11:30:01"/>
        <status last_op="update" date="2026-03-29T12:26:09"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137507.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137506" joint_id="137506">
        <published date="2026-03-23T05:20:00"/>
        <status last_op="update" date="2026-03-23T05:20:01"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137506.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137505" joint_id="137505">
        <published date="2026-03-13T20:01:00"/>
        <status last_op="update" date="2026-03-13T20:05:49"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137505.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137504" joint_id="137504">
        <published date="2026-02-24T12:15:00"/>
        <status last_op="update" date="2026-02-24T12:27:46"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[New real‑world data reinforce earlier use of Pluvicto® before chemotherapy in metastatic castration-resistant prostate cancer]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137504.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137503" joint_id="137503">
        <published date="2026-02-23T06:30:00"/>
        <status last_op="update" date="2026-02-23T06:30:02"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137503.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137502" joint_id="137502">
        <published date="2026-02-18T12:06:00"/>
        <status last_op="update" date="2026-02-18T12:18:44"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137502.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137501" joint_id="137501">
        <published date="2026-02-13T12:00:00"/>
        <status last_op="update" date="2026-02-13T12:53:44"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137501.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137500" joint_id="137500">
        <published date="2026-01-29T14:30:00"/>
        <status last_op="update" date="2026-01-29T15:38:47"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX: "Relax, It's a Blood Test"]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137500.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137499" joint_id="137499">
        <published date="2026-01-16T17:00:01"/>
        <status last_op="update" date="2026-01-16T17:00:02"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137499.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137497" joint_id="137497">
        <published date="2025-12-09T12:35:01"/>
        <status last_op="update" date="2025-12-09T12:35:02"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137497.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137498" joint_id="137498">
        <published date="2025-12-09T12:20:01"/>
        <status last_op="update" date="2025-12-09T12:20:03"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137498.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137495" joint_id="137495">
        <published date="2025-11-25T12:00:00"/>
        <status last_op="update" date="2025-11-25T12:00:01"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137495.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137496" joint_id="137496">
        <published date="2025-11-24T23:41:01"/>
        <status last_op="update" date="2025-11-24T23:48:22"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137496.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137494" joint_id="137494">
        <published date="2025-11-04T12:00:01"/>
        <status last_op="update" date="2025-11-04T13:06:43"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137494.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137493" joint_id="137493">
        <published date="2025-10-29T14:30:00"/>
        <status last_op="update" date="2025-10-29T14:30:01"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137493.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137492" joint_id="137492">
        <published date="2025-10-25T15:00:00"/>
        <status last_op="update" date="2025-10-25T15:00:02"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137492.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137491" joint_id="137491">
        <published date="2025-10-22T05:15:00"/>
        <status last_op="update" date="2025-10-22T05:31:49"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137491.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137490" joint_id="137490">
        <published date="2025-10-19T14:30:00"/>
        <status last_op="update" date="2025-10-19T14:44:48"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer ]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137490.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137489" joint_id="137489">
        <published date="2025-10-17T12:05:01"/>
        <status last_op="update" date="2025-10-17T12:05:02"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137489.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137488" joint_id="137488">
        <published date="2025-10-16T11:00:00"/>
        <status last_op="update" date="2025-10-16T12:23:52"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137488.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137487" joint_id="137487">
        <published date="2025-09-30T21:23:00"/>
        <status last_op="update" date="2025-09-30T21:26:24"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137487.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137486" joint_id="137486">
        <published date="2025-09-29T19:55:01"/>
        <status last_op="update" date="2025-09-29T21:06:57"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137486.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137485" joint_id="137485">
        <published date="2025-09-24T06:45:00"/>
        <status last_op="update" date="2025-09-24T11:03:48"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137485.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137484" joint_id="137484">
        <published date="2025-08-12T11:00:00"/>
        <status last_op="update" date="2025-08-12T11:03:44"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137484.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137483" joint_id="137483">
        <published date="2025-08-11T05:20:01"/>
        <status last_op="update" date="2025-08-11T05:21:54"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137483.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137482" joint_id="137482">
        <published date="2025-07-31T20:30:01"/>
        <status last_op="update" date="2025-07-31T20:53:54"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137482.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137481" joint_id="137481">
        <published date="2025-07-03T05:25:00"/>
        <status last_op="update" date="2025-07-03T10:42:30"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137481.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137480" joint_id="137480">
        <published date="2025-06-02T04:00:01"/>
        <status last_op="update" date="2025-06-02T07:16:26"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer ]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137480.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137479" joint_id="137479">
        <published date="2025-06-01T13:05:00"/>
        <status last_op="update" date="2025-06-01T13:46:30"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137479.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137478" joint_id="137478">
        <published date="2025-05-15T13:05:00"/>
        <status last_op="update" date="2025-05-15T13:05:01"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137478.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137476" joint_id="137476">
        <published date="2025-04-03T00:29:00"/>
        <status last_op="update" date="2025-04-03T01:23:24"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137476.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137475" joint_id="137475">
        <published date="2025-03-28T17:01:00"/>
        <status last_op="update" date="2025-03-28T17:06:54"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137475.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137474" joint_id="137474">
        <published date="2025-03-25T06:20:01"/>
        <status last_op="update" date="2025-03-25T11:12:38"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137474.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137473" joint_id="137473">
        <published date="2025-03-20T23:37:01"/>
        <status last_op="update" date="2025-03-25T00:19:08"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137473.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137472" joint_id="137472">
        <published date="2025-03-13T15:11:01"/>
        <status last_op="update" date="2025-03-13T15:31:48"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis named first-ever corporate pharmaceutical partner of the National Football League]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137472.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137471" joint_id="137471">
        <published date="2025-02-28T14:00:00"/>
        <status last_op="update" date="2025-02-28T14:52:53"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137471.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137470" joint_id="137470">
        <published date="2025-01-28T14:15:01"/>
        <status last_op="update" date="2025-02-04T17:05:24"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Early detection is a game changer: Novartis makes bold play to prioritize breast health and inspire a new wave of breast cancer screenings]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137470.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137469" joint_id="137469">
        <published date="2024-12-10T14:11:01"/>
        <status last_op="update" date="2024-12-10T14:29:57"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137469.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137468" joint_id="137468">
        <published date="2024-12-08T17:35:00"/>
        <status last_op="update" date="2024-12-08T17:35:01"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML ]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137468.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137467" joint_id="137467">
        <published date="2024-11-24T15:01:00"/>
        <status last_op="update" date="2024-11-25T06:35:02"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137467.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137466" joint_id="137466">
        <published date="2024-10-29T19:13:00"/>
        <status last_op="update" date="2024-10-29T19:17:59"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137466.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137465" joint_id="137465">
        <published date="2024-10-26T23:50:01"/>
        <status last_op="update" date="2024-10-26T23:50:01"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137465.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137464" joint_id="137464">
        <published date="2024-10-24T05:33:01"/>
        <status last_op="update" date="2024-10-29T23:09:35"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137464.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137463" joint_id="137463">
        <published date="2024-10-18T10:53:01"/>
        <status last_op="update" date="2024-10-18T11:34:15"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137463.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137462" joint_id="137462">
        <published date="2024-09-18T06:00:00"/>
        <status last_op="update" date="2024-09-18T13:23:31"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137462.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137461" joint_id="137461">
        <published date="2024-09-17T17:01:00"/>
        <status last_op="update" date="2024-09-17T18:32:32"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137461.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137460" joint_id="137460">
        <published date="2024-09-16T08:43:00"/>
        <status last_op="update" date="2024-09-16T08:44:01"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137460.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137459" joint_id="137459">
        <published date="2024-09-04T11:00:01"/>
        <status last_op="update" date="2024-09-04T11:02:45"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137459.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137458" joint_id="137458">
        <published date="2024-08-07T23:38:01"/>
        <status last_op="update" date="2024-08-12T15:44:39"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137458.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137457" joint_id="137457">
        <published date="2024-07-29T16:25:00"/>
        <status last_op="update" date="2024-07-29T16:28:51"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML ]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137457.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137456" joint_id="137456">
        <published date="2024-05-31T13:07:01"/>
        <status last_op="update" date="2024-05-31T13:13:31"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137456.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137455" joint_id="137455">
        <published date="2024-05-31T12:15:01"/>
        <status last_op="update" date="2024-06-13T20:49:46"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137455.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137454" joint_id="137454">
        <published date="2024-05-25T10:15:00"/>
        <status last_op="update" date="2024-05-26T06:28:34"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137454.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137453" joint_id="137453">
        <published date="2024-05-25T10:00:00"/>
        <status last_op="update" date="2024-05-26T06:27:16"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137453.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137452" joint_id="137452">
        <published date="2024-05-15T14:20:01"/>
        <status last_op="update" date="2024-05-15T14:45:58"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137452.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137451" joint_id="137451">
        <published date="2024-04-23T17:56:01"/>
        <status last_op="update" date="2024-04-23T18:01:51"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137451.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137450" joint_id="137450">
        <published date="2024-04-17T05:20:00"/>
        <status last_op="update" date="2024-04-18T15:49:56"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137450.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137449" joint_id="137449">
        <published date="2024-04-15T18:00:00"/>
        <status last_op="update" date="2024-04-15T19:00:28"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137449.intrado.xml"/>
      </press_release>
      <press_release language="en" type="5" id="137448" joint_id="137448">
        <published date="2024-04-06T20:16:01"/>
        <status last_op="update" date="2024-04-06T20:31:23"/>
        <categories>
          <category id="5" label="English" keywords="language"/>
          <category id="2890" label="Product" keywords="newstag"/>
        </categories>
        <release_tags>
          <keyword>Media Release</keyword>
          <keyword>Reimagine Medicine</keyword>
          <keyword>Innovation</keyword>
        </release_tags>
        <headline><![CDATA[New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting]]></headline>
        <location href="https://feeds.novartis.com/media-releases/us/production/us-media-releases/intrado/releases/137448.intrado.xml"/>
      </press_release>
    </press_releases>
  </body>
</hexML>
